All In Biotech

Drug Trial Radar · NCT06123715

Perioperative Vitamin C to Reduce Persistent Pain After Total Knee Arthroplasty

PeRiOperative VItamin C to Reduce perSistent paIn After tOtal kNee Arthroplasty (PROVISION): a Multicentre Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 3,216 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

3,216

Planned (sponsor's estimate)

Start

Apr 16, 2024

Primary completion

Dec 31, 2029

Study completion Dec 31, 2030

Sponsor

Lead sponsor
University Health Network, TorontoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Canadian Institutes of Health Research (CIHR); The Arthritis Society, Canada
First posted
Nov 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase III Multicentre, parallel-group, blinded, 1:1 randomized controlled trial to determine the effect of perioperative vitamin C supplementation on reducing the prevalence of persistent pain 3 months after total knee arthroplasty.

Conditions

  • Chronic Pain
  • Knee Pain Chronic
  • Post Operative Pain
  • Osteoarthritis, Knee

Interventions

  • Vitamin CDrug

    Drug: Patients in the intervention group will receive 2g Vitamin C orally within 4 hours of the start of the surgery followed by 500 mg of Vitamin C to be taken orally twice a day from post-op day 1 to day 56.

  • PlaceboDrug

    Drug: Patients in the placebo group will receive identical placebo capsules taken orally within 4 hours of the start of the surgery followed by placebo capsules taken orally twice a day from post-op day 1 to day 56.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Prevalence of persistent painTime frame: 3 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Mount Sinai Hospital

    Toronto, Ontario, Canada · Recruiting

  • Sunnybrook - Holland Centre

    Toronto, Ontario, Canada · Recruiting

  • Toronto Western Hospital

    Toronto, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.